On the role of hepatitis viruses in the etiology and pathogenesis of autoimmune liver diseases


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The development of autoimmune liver diseases (AILDs) is based on disorders in the functioning of the immune system, when autoantigens are perceived as foreign, which can lead to inflammation and destruction of liver tissue. Although the etiology of AILDs is not fully understood, it is most likely that a prerequisite for their development is the interaction of a number of genetic and environmental factors. There are certain haplotypes of human leukocyte antigen (HLA) that increase susceptibility to AILDs. At the same time, the simple presence of risk factors does not guarantee the onset of the disease, just as the presence of certain HLA haplotypes does not always lead to the development of AILDs; the etiopathogenetic relationships are much more complex. Epidemiological and molecular research data indicate that a number of pathogens (including viruses) may be responsible for the induction of AILDs. One of the mechanisms by which viruses can initiate and/or exacerbate AILDs is molecular mimicry, in which a foreign antigen has a common sequence or structural similarity to autoantigens. The review presents data indicating the probable role of hepatotropic viruses in the development of AILDs.

全文:

受限制的访问

作者简介

E. Sbikina

A.S. Loginov Moscow Clinical Scientific and Practical Center

Moscow, Russia

E. Vinnitskaya

A.S. Loginov Moscow Clinical Scientific and Practical Center

Moscow, Russia

Yu. Sandler

A.S. Loginov Moscow Clinical Scientific and Practical Center

Moscow, Russia

S. Batskikh

A.S. Loginov Moscow Clinical Scientific and Practical Center

Moscow, Russia

参考

  1. Czaja A.J. Diagnosis and management of autoimmune hepatitis. Clin Liver Dis. 2015 Feb;19(1):57-79. doi: 10.1016/j.cld.2014.09.004. PMID: 25454297
  2. Seldin M.F. The Genetics of Human Autoimmune Disease: A Perspective on Progress in the Field and Future Directions. J Autoimmun. 2015;64:1-12. doi: 10.1016/j.jaut.2015.08.015.
  3. Donaldson FIT., Doherty D.G., Hayllar K.M., et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 1991;13(4):701-6. PMID: 2010165.
  4. Manabe K, Donaldson F.T., Underhill J.A., et al. Human leukocyte antigen A1-B8-DR3-DQ2-DPB1*0401 extended haplotype in autoimmune hepatitis. Hepatology 1993;18(6):1334-37. PMID: 8244257.
  5. Czaja A.J., Strettell M.D., Thomson L.J., et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25(2):317-23. doi: 10.1002/hep.510250211. PMID: 9021941.
  6. Strettell M.D, Donaldson PT., Thomson L.J., et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997;112(6):2028-35. doi: 10.1053/gast.1997. v112.pm9178696. PMID: 9178696.
  7. Pando M., Larriba J., Fernandez G.C., et al. Pediatric and adult forms of type i autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30(6):1374-80. Doi: 10.1002/ hep.510300611. PMID: 10573514.
  8. Umemura T, Katsuyama Y, Yoshizawa K., et al. Human Leukocyte Antigen Class ii Haplotypes Affect Clinical Characteristics and Progression of Type1 Autoimmune Hepatitis in Japan. PLoS ONE.(2014;9(6):e100565. doi: 10.1371/journal.pone.0100565.
  9. Vazquez-Garcfa M.N., Alaez C., Olivo A., et al. MHC class ii sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol. 1998;28(6):985-90. doi: 10.1016/s0168-8278(98)80347-4. PMID: 9672174.
  10. Czaja A.J., Carpenter H.A., Santrach P.J., Moore S.B. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105(5):1502-507. doi: 10.1016/0016-5085(93)90157-8. PMID: 8224654.
  11. Donaldson P.T. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut. 2004;53:599-608. doi: 10.1136/gut.2003.031732.
  12. Ma Y, Bogdanos D.P, Hussain M.J., et al. Polyclonal T-cell responses to cytochrome P450iiD6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology. 2006;130(3):868-82. doi: 10.1053/j.gastro.2005.12.020. PMID: 16530525
  13. Djilali-Saiah i., Renous R., Caillat-Zucman S., et al. Linkage disequilibrium between HLA class ii region and autoimmune hepatitis in pediatric patients. J Hepatol. 2004;40:904-9. doi: 10.1016/j.jhep.2006.07.034.
  14. Liberal R., Krawitt E.L., Vierling J.M., et al. Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016;75:6-19. doi: 10.1016/j.jaut.2016.07.005. PMID: 27502148.
  15. Karlsen T.H., Franke A., Melum E., et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138(3):1102-11. doi: 10.1053/j.gastro.2009.11.046. PMID: 19944697.
  16. Melum E., Franke A., Schramm C., et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43(1):17-9. doi: 10.1038/ng.728. PMID: 21151127; PMCiD: PMC4354850.
  17. Gidwaney N.G., Pawa S., Das K.M. Pathogenesis and clinical spectrum of primary sclerosing cholangitis. World J Gastroenterol. 2017;23(14):2459-69. doi: 10.3748/wjg.v23.i14.2459.
  18. Spurkland A., Saarinen S., Boberg K.M., et al. HLA class ii haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens. 1999;53:459-469.
  19. Mells G.F., Pells G., Newton J.L., et al. impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58(1):273-83. doi: 10.1002/hep.26365. PMID: 23471852.
  20. Eksteen B. Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis. Br Med Bull. 2014;110(1):89-98. doi: 10.1093/bmb/ldu008. PMID: 24795363.
  21. Hirschfield G.M., Liu X., Han Y, et al. Variants at iRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010;42(8):655-57. doi: 10.1038/ng.631. PMID: 20639879; PMCiD: PMC2929126.
  22. Nakamura M., Nishida N., Kawashima M., et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet. 2012;91(4):721-28. Doi: 10.1016/j. ajhg.2012.08.010. PMID: 23000144; PMCiD: PMC3484650.
  23. Qiu F., Tang R., Zuo X., et al. A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. Nat Commun. 2017;8:14828. doi: 10.1038/ncomms14828.
  24. Kawashima M., Hitomi Y, Aiba Y., et al. Genome wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. Hum Mol Genet. 2017;26(3):650-59. doi: 10.1093/hmg/ddw406. PMID: 28062665.
  25. Jones D.E., Watt F.E., Metcalf J.V., et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol. 1999;30(3):402-7. doi: 10.1016/s0168-8278(99)80097-x. PMID: 10190721.
  26. Lazaridis K.N., Juran B.D., Boe G.M., et al. increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology. 2007;46(3):785-92. Doi: 10.1002/ hep.21749. PMID: 17680647.
  27. Selmi C., Mayo M.J., Bach N., et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127(2):485-92. Doi: 10.1053/j. gastro.2004.05.005. PMID: 15300581.
  28. Wakabayashi K., Lian Z.X., Leung P.S., et al. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology. 2008;48(2):531-40. doi: 10.1002/hep.22390. PMID: 18563844; PMCiD: PMC3753011.
  29. Christen U., Hintermann E. Pathogens and autoimmune hepatitis. Clin Exp immunol. 2019;195(1):35-51. doi: 10.1111/cei.13203.
  30. Manfredo Vieira S., Hiltensperger M., Kumar V., et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018;359(6380):1156-61. doi: 10.1126/science.aar7201. Erratum in: Science. 2018;360(6388): PMID: 29590047; PMCiD: PMC5959731.
  31. Christen U., von Herrath M.G. Do viral infections protect from or enhance type 1 diabetes and how can we tell the difference? Cell Mol immunol. 2011;8(3):193-98. doi: 10.1038/cmi.2010.71.
  32. Тареев Е.М. Эволюция учения о сывороточном гепатите. Советская медицина. 1975;5:27-37. [Tareev E.M. Evolution of the doctrine of serum hepatitis. Sovetskaya meditsina. 1975;5:27-37. (in Russ.)].
  33. Von Herrath M.G., Fujinami R.S., Whitton J.L. Microorganisms and autoimmunity: making the barren field fertile? Nat Rev Microbiol. 2003;1(2):151-57. doi: 10.1038/nrmicro754. PMID: 15035044.
  34. Llewelyn M., Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet infect Dis. 2002;2(3):156-62. doi: 10.1016/s1473- 3099(02)00222-0.
  35. Cusick M.F., Libbey J.E., Fujinami R.S. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy immunol 2012;42:102-11. doi: 10.1007/s12016-011-8294-7.
  36. Manns M.P Hepatotropic viruses and autoimmunity. 1997;(4 Suppl 1):7-10. doi: 10.1111/j.1365-2893.1997.tb00154.x.
  37. Singh G., Palaniappan S., Rotimi O., Hamlin P.J. Autoimmune hepatitis triggered by hepatitis A. Gut. 2007:56;304. doi: 10.1136/gut.2006.111864.
  38. Atsushi Tanaka. Autoimmune Hepatitis: Gut Liver 2020;14(4):430-38. doi: 10.5009/gnl19261.
  39. Tabak F., Ozdemir F., Tabak O., et al. Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. Ann Hepatol. 2008; 7(2):177-79. doi: 10.1016/S1665-2681(19)31878-2.
  40. Vento S, Garofano T., Di Perri G., et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337(8751):1183-87. doi: 10.1016/0140-6736(91)92858-y PMID: 1673738.
  41. Bogdanos D.-P, Mieli-Vergani G., Vergan D. Virus, liver and autoimmunity Digestive and Liver Disease. 2000;32(5):440-46. doi: 10.1016/S1590-8658(00)80266-2.
  42. Eddleston A.L., Williams R. Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet. 1974;2(7896):1543-45. doi: 10.1016/s0140-6736(74)90287-6. PMID: 4140983.
  43. Vento S., McFarlane B.M., McSorley C.G., et al. Liver autoreactivity in acute virus A, B and non-A, non-B hepatitis. J Clin Lab Immunol. 1988;25(1):1-7. PMID: 3133482.
  44. Sostre V, Patel H.G., Mohamed A., Volfson A. A Case of Acute Autoimmune Hepatitis Superimposed on Chronic Hepatitis B Infection. Case Rep Gastrointest Med. 2018;2018:2139607. doi: 10.1155/2018/2139607. PMID: 29805819; PMCID: PMC5899862.
  45. Shih C, Chou S.-F., Yang C.-C., et al. Control and Eradication Strategies of Hepatitis B. Virus. Trends Microbiol. 2016;24(9):739-49. Doi: 10.1016/j. tim.2016.05.006.
  46. Kim D.H., Kim S.B. Hepatic Failure by Spontaneous Reactivation of Hepatitis B Virus without a Trigger Factor in a Patient with Anti-HBs. Case Rep Gastroenterol. 2018;12(2):286-91. doi: 10.1159/000490099.
  47. Georgiadou S.P, Zachou K., Liaskos C., et al. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Internat. 2009;29(3):434-42. doi: 10.1111/j.1478-3231.2008.01851.x
  48. Czaja A.J., Carpenter H.A., Santrach PJ., et al. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol. 1993;18(3):342-52. doi: 10.1016/s0168-8278(05)80279-x
  49. Lohse A.W., Gerken G., Mohr H., et al. Relation between autoimmune liver diseases and viral hepatitis: clinical and serological characteristics in 859 patients. Zeitschrift fur Gastroenterologie. 1995;33(9):527-33.
  50. Murakami K. Okazaki H.M., Fujii K., et al. Hepatitis B virus carrier status linked to autoimmune hepatitis. 1996;35(6):468-71. Doi: 10.2169/ internalmedicine.35.468.
  51. Be land K., Lapierre P, Alvarez F. World J Gastroenterol. Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. 2009;15(9):1025-34. doi: 10.3748/wjg.15.1025.
  52. Maya R., Gershwin M.E., Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol. 2008;34(1):85-102. Doi: 10.1007/ s12016-007-8013-6. PMID: 18270862 Review.
  53. Pawlowska M., Halota W. Acute liver failure caused by concurrent autoimmune hepatitis and hepatitis B in a 16-year old girl. World J Hepatol. 2010;2(10):392-94. doi: 10.4254/wjh.v2.i10.392.
  54. Bcheur H., Valla D., Loriot M. A., et al. Concurrent emergence of hepatitis B e antigen-negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate. Digestive Diseases and Sciences. 1998;43(11):2479-82.
  55. Taubert R., Diestelhorst J., Junge N., et al. Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. Sci Rep. 2018;8:17452. Doi: 10.1038/ s41598-018-35882-7.
  56. Narciso-Schiavon J.L., de Schiavon L.L. Autoantibodies in chronic hepatitis C: A clinical perspective. World J Hepatol. 2015;7(8):1074-85. doi: 10.4254/wjh. v7.i8.1074.
  57. Chretien P., Chousterman M., Abd Alsamad I., et al. Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis. J Autoimmun. 2009;32(3-4):201-5. doi: 10.1016/j.jaut.2009.02.005. PMID: 19324518.
  58. Amoras Eda S., Gomes S.T., Freitas F.B., et al. Intrahepatic mRNA Expression of FAS, FASL, and FOXP3 Genes Is Associated with the Pathophysiology of Chronic HCV Infection. PLoS One. 2016;11(5):e0156604. doi: 10.1371/journal.pone.0156604.
  59. Fouad H., El Raziky M., Hassan E.M., et al. Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity. World J Hepatol. 2016;8(30):1287-94. doi: 10.4254/wjh. v8.i30.1287.
  60. Sezaki H., Arase Y, Tsubota A., et al. Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol. 2003;38(5):493-500. Doi: 10.1007/ s00535-002-1090-7. PMID: 12768394.
  61. Sugiura A., Wada S., Mori H., et al. Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir. Case Rep Gastroenterol. 2017;11:305-11. doi: 10.1159/000475752.
  62. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256-71. Doi: 10.1016/j. jhep.2018.03.005. PMID: 29609832.
  63. Yan B., Zhang L., Gong L., et al. Hepatitis E Virus in Yellow Cattle, Shandong, Eastern China. Emerg Infect Dis. 2016;22(12):2211-12. Doi:10.3201/ eid2212.160641.
  64. van Gerven N.M., van der Eijk A.A., Pas S.D., et al. Dutch Autoimmune Hepatitis Study Group. Seroprevalence of Hepatitis E Virus in Autoimmune Hepatitis Patients in the Netherlands. J Gastrointestin Liver Dis. 2016;25(1):9-13. doi: 10.15403/jgld.2014.1121.251.hpe. PMID: 27014749.
  65. Le Cann P., Tong M.J., Werneke J., Coursaget P. Detection of antibodies to hepatitis E virus in patients with autoimmune chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol. 1997;32(4):387-89. doi: 10.3109/00365529709007689. PMID: 9140163.
  66. Pischke S., Gisa A., Suneetha P.V, et al. Increased HEV seroprevalence in patients with autoimmune hepatitis. PLoS One. 2014;9(1):e85330. doi: 10.1371/journal. pone.0085330.
  67. Eder M., Strassl R., Beinhardt S., et al. High seroprevalence of anti-Hepatitis E antibodies in Austrian patients with autoimmune hepatitis. Liver Int. 2019;39(4):640-45. doi: 10.1111/liv.14005. PMID: 30431228.
  68. Terziroli Beretta-Piccoli B., Ripellino P., Gobbi C., et al. Autoimmune Hepatitis Cohort Study Group. Autoimmune liver disease serology in acute hepatitis E virus infection. J Autoimmun. 2018;94:1-6. doi: 10.1016/j.jaut.2018.07.006. PMID: 30336842.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##